Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $921.00 Price Target at Sanford C. Bernstein

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price reduced by Sanford C. Bernstein from $925.00 to $921.00 in a research note published on Wednesday morning,Benzinga reports. Sanford C. Bernstein currently has an outperform rating on the biopharmaceutical company’s stock.

A number of other brokerages have also recently issued reports on REGN. Wells Fargo & Company raised their target price on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a report on Monday, February 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. Zacks Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. JPMorgan Chase & Co. raised their target price on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Finally, Piper Sandler assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 31st. They set an “overweight” rating and a $875.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $810.78.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $775.53 on Wednesday. The stock has a 50-day moving average price of $766.90 and a 200 day moving average price of $717.58. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The firm has a market cap of $81.99 billion, a price-to-earnings ratio of 18.66, a PEG ratio of 2.02 and a beta of 0.40. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s revenue was up 2.5% on a year-over-year basis. During the same period last year, the company earned $12.07 earnings per share. Research analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were issued a dividend of $0.94 per share. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.05%.

Insider Activity

In other news, SVP Jason Pitofsky sold 2,036 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president owned 4,272 shares in the company, valued at $3,325,837.44. The trade was a 32.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the transaction, the director owned 1,703 shares in the company, valued at $1,330,604.99. This trade represents a 49.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,774 shares of company stock worth $2,942,738 in the last 90 days. Corporate insiders own 7.02% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. WPG Advisers LLC raised its position in Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 25 shares during the last quarter. SHP Wealth Management acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $26,000. Salomon & Ludwin LLC acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Titan Wealth CI Ltd acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $29,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $31,000. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.